AIM: To investigate the progression of hepatic histopathology in serial liver biopsies from Wilson disease (WD) patients. METHODS: We report a group of 12 WD patients treated with zinc and/or penicillamine who underwent multiple follow-up liver biopsies. Demographic, clinical and laboratory data were gathered and all patients underwent an initial biopsy and at least one repeat biopsy. RESULTS: Time to repeat biopsy ranged from 2 to 12 years. Six patients (non-progressors) showed stable hepatic histology or improvement. In one case, we observed improvement of fibrosis from stage 2 to 0. Six patients (progressors) had worsening of fibrosis. There was no significant correlation between the histological findings and serum aminotransferases or copper metabolism parameters. The hepatic copper concentration reached normal levels in only two patients: one from the non-progressors and one from the progressors group. The estimated rate of progression of hepatic fibrosis in the entire group was 0 units per year in the time frame between the first and the second liver biopsy (4 years), and 0.25 between the second and the third (3 years). In the progressors group, the rate of progression of liver fibrosis was estimated at 0.11 fibrosis units per year between the first and second biopsy and, 0.6 fibrosis units between the second and third biopsy. CONCLUSION: The inability of clinical tools to detect fibrosis progression in WD suggests that a liver biopsy with hepatic copper quantification every 3 years should be considered.
AIM: To investigate the progression of hepatic histopathology in serial liver biopsies from Wilson disease (WD) patients. METHODS: We report a group of 12 WDpatients treated with zinc and/or penicillamine who underwent multiple follow-up liver biopsies. Demographic, clinical and laboratory data were gathered and all patients underwent an initial biopsy and at least one repeat biopsy. RESULTS: Time to repeat biopsy ranged from 2 to 12 years. Six patients (non-progressors) showed stable hepatic histology or improvement. In one case, we observed improvement of fibrosis from stage 2 to 0. Six patients (progressors) had worsening of fibrosis. There was no significant correlation between the histological findings and serum aminotransferases or copper metabolism parameters. The hepatic copper concentration reached normal levels in only two patients: one from the non-progressors and one from the progressors group. The estimated rate of progression of hepatic fibrosis in the entire group was 0 units per year in the time frame between the first and the second liver biopsy (4 years), and 0.25 between the second and the third (3 years). In the progressors group, the rate of progression of liver fibrosis was estimated at 0.11 fibrosis units per year between the first and second biopsy and, 0.6 fibrosis units between the second and third biopsy. CONCLUSION: The inability of clinical tools to detect fibrosis progression in WD suggests that a liver biopsy with hepatic copper quantification every 3 years should be considered.
Authors: Matilde Marcellini; Vincenzo Di Ciommo; Francesco Callea; Rita Devito; Donatella Comparcola; Maria Rita Sartorelli; Giovanni Carelli; Francesco Carelli; Valerio Nobili Journal: J Lab Clin Med Date: 2005-03
Authors: G Faa; V Nurchi; L Demelia; R Ambu; G Parodo; T Congiu; R Sciot; P Van Eyken; R Silvagni; G Crisponi Journal: J Hepatol Date: 1995-03 Impact factor: 25.083
Authors: Valentina Medici; Dorothy A Kieffer; Noreene M Shibata; Harpreet Chima; Kyoungmi Kim; Angela Canovas; Juan F Medrano; Alma D Islas-Trejo; Kusum K Kharbanda; Kristin Olson; Ruijun J Su; Mohammad S Islam; Raisa Syed; Carl L Keen; Amy Y Miller; John C Rutledge; Charles H Halsted; Janine M LaSalle Journal: Epigenetics Date: 2016-09-09 Impact factor: 4.528
Authors: Charles E Mordaunt; Noreene M Shibata; Dorothy A Kieffer; Anna Czlonkowska; Tomasz Litwin; Karl Heinz Weiss; Daniel N Gotthardt; Kristin Olson; Dongguang Wei; Stewart Cooper; Yu-Jui Yvonne Wan; Mohamed R Ali; Janine M LaSalle; Valentina Medici Journal: Hum Mol Genet Date: 2018-11-15 Impact factor: 6.150
Authors: Valentina Medici; Noreene M Shibata; Kusum K Kharbanda; Janine M LaSalle; Rima Woods; Sarah Liu; Jesse A Engelberg; Sridevi Devaraj; Natalie J Török; Joy X Jiang; Peter J Havel; Bo Lönnerdal; Kyoungmi Kim; Charles H Halsted Journal: Hepatology Date: 2013-01-10 Impact factor: 17.425
Authors: Peter Ott; Aurélia Poujois; Thomas Damgaard Sandahl; Karl Heinz Weiss; Peter Ferenci; Michael L Schilsky; Aftab Ala; Frederick K Askari; Anna Czlonkowska; Ralf-Dieter Hilgers; Eve A Roberts Journal: Hepatology Date: 2021-10-05 Impact factor: 17.298